Pfizer: what’s next for the Covid-19 vaccine maker and its US$28 billion war chest?

Pfizer’s Covid-19 vaccine saw the pharmaceutical company become the world’s most visible drug maker, but with its stock falling in 2022, success has left investors impatient for an encore.

Read the original article at South China Morning Post